JOSÉ LUIS PEDRAZ MUÑOZ-rekin lankidetzan egindako argitalpenak (24)

2022

  1. Three-dimensional printing as a cutting-edge, versatile and personalizable vascular stent manufacturing procedure: Toward tailor-made medical devices

    International Journal of Bioprinting, Vol. 9, Núm. 2, pp. 219-255

2021

  1. Design and validation of a process based on cationic niosomes for gene delivery into novel urine-derived mesenchymal stem cells

    Pharmaceutics, Vol. 13, Núm. 5

  2. Gernutik lortutako zelula ama mesenkimalak (hUSC) pseudohipoparatiroidismoaren (PHP)terapia geniko ez-biralerako

    Osasun zientzak: IV. Ikergazte Nazioarteko Ikerteta Euskaraz. 2021eko ekainaren 9, 10 eta . Gasteiz, Euskal Herria.

2019

  1. Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 18, pp. 101-111

2017

  1. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications

    International Journal of Pharmaceutics, Vol. 523, Núm. 2, pp. 556-566

2016

  1. LL37 loaded nanostructured lipid carriers (NLC): A new strategy for the topical treatment of chronic wounds

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 108, pp. 310-316

2015

  1. The topical administration of rhEGF-loaded nanostructured lipid carriers (rhEGF-NLC) improves healing in a porcine full-thickness excisional wound model

    Journal of controlled release : official journal of the Controlled Release Society, Vol. 197, pp. 41-47

2014

  1. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice

    Journal of Controlled Release, Vol. 185, Núm. 1, pp. 51-61

2013

  1. RhEGF-loaded PLGA-Alginate microspheres enhance the healing of full-thickness excisional wounds in diabetised Wistar rats

    European Journal of Pharmaceutical Sciences, Vol. 50, Núm. 3-4, pp. 243-252

2011

  1. Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 3, pp. 167-173

2008

  1. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy

    Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180

  2. Utilización de antimicrobianos en las infecciones odontogénicas en niños y adolescentes: Análisis farmacocinético/farmacodinámico (PK/PD)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 10, pp. 621-628

2007

  1. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies

    Chemotherapy, Vol. 53, Núm. 3, pp. 194-201

2006

  1. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: Evaluation of the sieving coefficient

    Blood Purification, Vol. 24, Núm. 4, pp. 347-354

2005

  1. Análisis farmacocinético/farmacodinámico (PK/PD) de la antibioterapia en odontoestomatología

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 23, Núm. 3, pp. 116-121

  2. Cefepime and continuous renal replacement therapy (CRRT): In vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients

    Clinical Therapeutics, Vol. 27, Núm. 5, pp. 599-608

  3. Determination of ceftazidime and cefepime in plasma and dialysate-ultrafiltrate from patients undergoing continuous veno-venous hemodiafiltration by HPLC

    Journal of Pharmaceutical and Biomedical Analysis, Vol. 39, Núm. 5, pp. 996-1005

  4. Evaluation of antimicrobial treatments in children with acute otitis media in Spain: A pharmacokinetic-pharmacodynamic (PK/PD) approach

    Journal of Chemotherapy, Vol. 17, Núm. 6, pp. 628-635

  5. Influence of renal function on the pharmacokinetics of piperacillin/ tazobactam in intensive care unit patients during continuous venovenous hemofiltration

    Journal of Clinical Pharmacology, Vol. 45, Núm. 2, pp. 168-176

  6. Meropenem and continuous renal replacement therapy: In vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients

    Journal of Clinical Pharmacology, Vol. 45, Núm. 11, pp. 1294-1304